viewConsort Medical PLC

Delays to Mylan’s Wixela inhaler to hit Consort Medical’s annual profits by £3mln

The US FDA has twice rejected Wixela, and despite Mylan’s claims that approval is around the corner, the green light is yet to be shown

man coughing
Consort is responsible for designing and making the Wixela inhaler

Consort Medical PLC (LON:CSRT) has warned it will take a £3mln hit this year from delays with Mylan’s (NASDAQ:MYL) Wixela inhaler, the generic version of GlaxoSmithKline PLC’s (LON:GSK) Advair chronic lung disease treatment.

US regulators shot down Wixela for a second time in June, after which Mylan bosses said they hoped to gain approval for the device by mid-October. A week into December, and the green light is still yet to be seen.

Consort is making the inhaler itself, while its Mylan’s job to devise the formula for the drug.

“Due to the delay with Mylan in their Wixela (generic Advair) programme, the board expects profit before tax for the current financial year to be adversely impacted by approximately £3mln as compared to their previous forecast,” said chief executive Jonathan Glenn.

“Whilst the delay in approval of this programme and near-term anticipated negative impact on our business is disappointing, our view of the peak sales opportunity for the product remains unchanged.”

That message didn’t quite chime with what analysts had previously said, with Wells Fargo claiming back in October that the delays meant the opportunity was “rapidly diminishing”.

The news came alongside Consort’s interim results, which showed a slight drop in revenue to £152.5mln in the soc months ended October 31 (H1 17: £153.7mln).

Adjusted pre-tax profits rose 6% though to £19.0mln (H1 17: £17.9mln), reflecting a lower pension charge and tax rate. The company nudged its interim dividend up 2.2% to 7.60p.

Shares fell 20.5% to 780p on Tuesday.

Quick facts: Consort Medical PLC

Price: - -

Market: LSE
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Arcadia Biosciences reports strong 2Q revenue despite coronavirus impact

Arcadia Biosciences Inc (NASDAQ:RKDA) CEO Matthew Plavan tells Proactive the California-based group's 2Q revenue growth was fueled by GLA sales and GoodWheat royalties. Plavan says the company also cinched a trio of recent GoodWheat agreements: a collaboration with Corner Foods to bring its...

5 hours, 1 minute ago

2 min read